ECPC is the unified voice of cancer patients across Europe!
The European Cancer Patient Coalition (ECPC) works for a Europe of equality, where all European cancer patients have timely and affordable access to the best treatment and care available, throughout their life. ECPC believes that cancer patients are the most important partners in the fight against cancer and against all the cancer-related issues affecting our society. Policy makers, researchers, doctors and industry should recognise cancer patients as co-creators of their own health.
The European cancer patient Coalition participates in several European Union's Research and Innovation framework programmes, among others: this includes IMI 1 projects, the Seventh Framework Programme (FP7), and IMI 2 projects under the current Horizon 2020 (H2020).ECPC's participation in calls look into the basic principle of incoporating European added value to current Members' activities. The European Commission defines European added value, under the 3rd Health Programme, as "additional to the value created by actions of individual Member States. It may result from different factors, e.g. coordination gains, legal certainty, greater effectiveness or complementarities. It reflects broader European relevance and significance of the action with a view to presenting models and mechanisms which can be applied not only regionally or nationally but also EU widely."
ECPC is one of the few patient organisations directly involved in research. The European Cancer Patient Coalition draws on fundamental knowledge and understanding of the patients' situation by working through our Members. Its "on the field" engagement enhances ECPC's capacity to truly represent patients at the EU level, providing irreplaceable first-hand understanding of the issues revolving around cancer patients. Furthermore, EU funded research projects allow us to be on the forefront of scientific developments on cancer by providing the patient's perspective while draining fundamental knowledge on the science behind cancer.